Endocrine Abstracts

Objectives: Endogenous Cushing’s Syndrome (CS) is a rare, chronic condition that results in high morbidity, caused by prolonged exposure to elevated levels of circulating free cortisol levels. Osilodrostat, a newly approved steroidogenesis inhibitor, has been shown to achieve fast and high rates of cortisol normalization, improving manifestations of hypercortisolism in patients with Cushing’s Disease (CD), a form of CS. We evaluated relative complete response (CR) ou...

Background: Bilateral adrenalectomy (BLA) is a treatment option for patients suffering from endogenous Cushing syndrome (CS). It consists of the surgical removal of both adrenal glands. Even though BLA offers immediate control of cortisol excess, given the risk of adrenal insufficiency, it requires life-long glucocorticoid and mineral corticoid replacement. It may lead to perioperative and long-term complications which affect patients’ quality of life (QoL). Health state ...

Introduction: Acromegaly is associated with significant morbidity and reduced quality of life. A robust clinical programme (14 trials) established pasireotide as an effective second-generation somatostatin receptor ligand for the treatment of various endocrine conditions, including acromegaly. Patients who completed a previous pasireotide trial and continued to receive clinical benefit, according to the parent study investigator, could continue treatment in the B2412 rollover ...